期刊
JOURNAL OF CONTROLLED RELEASE
卷 155, 期 3, 页码 435-441出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2011.05.025
关键词
PSMA aptamer; Dendrimers; Doxorubicin; Targeted chemoimmunotherapy; Cancer therapy
资金
- Ministry for Health, Welfare & Family Affairs, Republic of Korea [A084764-0902-0000100]
- National Research Foundation of Korea (NRF)
- Ministry of Education, Science and Technology [20100028753]
We reported an innovative, targeted chemoimmuno drug-delivery system. Although chemoimmunotherapy, as an alternative to or in combination with conventional therapeutic systems, has been in the forefront of recent oncological research, as presently configured, such systems face several major obstacles for efficient clinical application. Here, we establish a novel nano-platform for effective chemoimmunotherapy designed to overcome the drawbacks of conventional cancer therapies, describing a delivery system based on a dendrimer and a single-strand DNA-A9 PSMA (prostate-specific membrane antigen) RNA aptamer hybrid. Employing these vehicles, we demonstrate the promising possibility of this chemoimmuno therapeutic system against prostate cancer in in vivo and in vitro models. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据